New drug ZW251 targets Hard-to-Treat cancers in early trial
NCT ID NCT07164313
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 24 times
Summary
This early-phase study tests a new drug called ZW251 in people with advanced liver cancer, a type of lung cancer, or certain germ cell tumors. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The main goals are to check safety and find the right dose, with about 100 participants expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERM CELL TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinica Universidad de Navarra
RECRUITINGPamplona, 31008, Spain
Contact
-
Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
Contact
-
Hospital Universitario Vall d'Hebron
RECRUITINGBarcelona, 08035, Spain
Contact
-
Hospital Universitario Virgen de la Victoria
RECRUITINGMálaga, 29010, Spain
Contact
-
Kansai Medical University Hospital
RECRUITINGOsaka, 573-1191, Japan
Contact
-
Kyoto University Hospital
RECRUITINGKyoto, 606-8507, Japan
Contact
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065-6800, United States
Contact
-
NEXT Oncology Madrid
RECRUITINGMadrid, 28223, Spain
Contact
-
National Cancer Center East
RECRUITINGKashiwa, 2778577, Japan
Contact
-
National Cancer Center Hospital
RECRUITINGTokyo, 104-0045, Japan
Contact
-
National Taiwan University Hospital
RECRUITINGTaipei, 100225, Taiwan
Contact
-
Norton Cancer Institute
RECRUITINGLouisville, Kentucky, 40202, United States
Contact
-
START - Dublin Mater Misericordiae University Hospital (MMUH)
RECRUITINGDublin, D07 R2WY, Ireland
Contact
-
START - Rioja Hospital Universitario San Pedro
RECRUITINGLogroño, 26006, Spain
Contact
-
START Barcelona
RECRUITINGBarcelona, 29010, Spain
Contact
-
START Lisboa a - Unidade de Ensaios ClÃnicos - Hospital de Santa Maria
RECRUITINGLisbon, 1649-035, Portugal
Contact
-
START Madrid Hospital Universitario Fundacion Jimenez Diaz
RECRUITINGMadrid, 28040, Spain
Contact
-
START Madrid Hospital Universitario HM Sanchinarro - CIOCC
RECRUITINGMadrid, 28050, Spain
Contact
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact
-
START San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
-
Taipei Veterans General Hospital
RECRUITINGTaipei, 112201, Taiwan
Contact
-
UCSF Comprehensive Cancer Center
RECRUITINGSan Francisco, California, 94158, United States
Contact
-
Unidade Local de Saúde Gaia e Espinho
RECRUITINGVila Nova de Gaia, 4434-502, Portugal
Contact
-
University of California Los Angeles - Cancer Care - Santa Monica (UCLA)
RECRUITINGSanta Monica, California, 90404, United States
Contact
Conditions
Explore the condition pages connected to this study.